Clinical Trial Update: Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating irinotecan and docetaxel in metastatic or unresectable gastric or gastroesophageal junction adenocarcinoma has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Neoplasms
• Gastric Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Irinotecan (Irinotecan)

Snippet

Sponsor: University of Southern California | Conditions: Gastric Cancer, Esophageal Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2018-02-19